Clinical Scorecard: Was the GLP-1 Problem Always Cost?
At a Glance
| Category | Detail |
|---|---|
| Condition | Obesity |
| Key Mechanisms | GLP-1 and GLP-1/GIP receptor agonist medications targeting obesity |
| Target Population | Medicare Part D and state Medicaid beneficiaries with obesity |
| Care Setting | Medicare and Medicaid programs, outpatient clinical management |
Key Highlights
- CMS BALANCE model aims to negotiate standardized pricing and coverage for GLP-1 medications.
- Discontinuation of GLP-1 therapies is driven more by cost and insurance issues than adverse effects.
- Success of the BALANCE model depends on voluntary participation by state Medicaid programs and Medicare Part D plans.
Guideline-Based Recommendations
Diagnosis
- Recognize obesity as a disease requiring medical treatment rather than a lifestyle choice.
Management
- Utilize GLP-1 and GLP-1/GIP receptor agonists for obesity management when accessible.
- Advocate for participation in the BALANCE model to improve medication access and affordability.
Monitoring & Follow-up
- Monitor patient adherence, noting that financial barriers significantly impact continuation of therapy.
Risks
- Discontinuation risk is primarily related to cost and insurance coverage rather than adverse effects.
Patient & Prescribing Data
Medicare Part D and state Medicaid beneficiaries with obesity
Removing financial barriers can improve adherence to levels seen in clinical trials; cost remains a major factor in discontinuation.
Clinical Best Practices
- Educate clinicians on upcoming policy changes affecting GLP-1 medication access in 2026.
- Engage in advocacy efforts encouraging state Medicaid and Medicare Part D participation in the BALANCE model.
- Address structural barriers to medication adherence by understanding insurance and cost dynamics.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
